Management of allogeneic stem cell transplantation for high-risk AML following SARS-CoV-2 associated pancytopenia with marked bone marrow biopsy alterations
| Autor: | Rebecca Lloyd, Evgenia Xenou, Hannah Giles, Maria Kaparou, Richard Lovell, Saleena Chauhan, Hansini Dassanayake, Zbigniew Rudzki, Vidhya Murthy, Alexandros Kanellopoulos, Beena Salhan, Shankara Paneesha, Claire Horgan, Joanne Ewing, Bhuvan Kishore, Maria Zahid Ahmed, Swathy Srinath, Anand Lokare, Emmanouil Nikolousis |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Pathology
medicine.medical_specialty medicine.diagnostic_test business.industry medicine.medical_treatment Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Case Report General Medicine Hematopoietic stem cell transplantation Matched Unrelated Donor 030204 cardiovascular system & hematology medicine.disease Pancytopenia Transplantation 03 medical and health sciences 0302 clinical medicine medicine.anatomical_structure 030220 oncology & carcinogenesis Biopsy medicine Diseases of the blood and blood-forming organs Bone marrow Stem cell RC633-647.5 business |
| Zdroj: | Case Reports in Hematology Case Reports in Hematology, Vol 2021 (2021) |
| ISSN: | 2090-6560 |
| Popis: | The present study describes a patient aged 70 with very high-risk AML who successfully received a nonmyeloablative matched unrelated donor allograft shortly following SARS-CoV-2 infection, which manifested with mild cough, interstitial abnormalities on chest CT, and pancytopenia with profound bone marrow biopsy histological alterations. In parallel, our study provides bone marrow biopsy data in a series of contemporary patients with serious haematological diseases who had a bone marrow biopsy performed within two weeks of PCR confirmation of SARS-CoV-2 infection. This study is notable because there are no published data describing the bone marrow biopsy changes observed in patients with haematological malignancies and SARS-CoV-2 infection. Finally, it is suggested that nonmyeloablative hematopoietic stem cell transplantation for very high-risk haematological malignancies can be successfully performed following recovery from SARS-CoV-2 infection. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text